It happens to us all at some time or another, but with an expected frequency on New Year’s Eve. We drink too much, and then we pay for it the next day. Are you hung up by your hangover?
Well, let me explain what is going on with your body and help you figure out ways to deal with the problems at hand.
Symptom: Dehydration
Your throat and mouth are dry due to dehydration, which is caused by the diuretic properties of alcohol. The dehydration also affects your muscles making them feel weak.
Cure: Drink plenty of water, all day long!
Symptom: Sour Stomach
The excessive alcohol irritates the lining of the stomach causing nausea and sour stomach. The inflammation delays digestion, which in turn, contributes to the feelings of nausea.
Cure: Take some Alka Seltzer or eat some mild foods.
Symptom: Irritability
Your liver gets backed up trying to metabolize all the alcohol so you might be experiencing symptoms of hypoglycemia (that’s a fancy term for low blood sugar), meaning you are highly irritable and moody.
Cure: Eat some food and drink some juice.
Symptom: Jangled Nerves
Your central nervous system becomes chemically over excited causing sensitivity to light, sound and touch.
Cure: Rest with an eye pillow and soothing music.
Symptom: Headache
Blood vessels in the brain dilate and that is what is causing that throbbing headache, which is only exacerbated by your dehydration mentioned above.
Cure: Take some OTC (over the counter) pain medication.
Sleepy and Sleepless: Your pituitary gland becomes confused and releases the wrong amounts of the hormones that regulate sleep. So while you may want to sleep it off, your sleep pattern is severely disrupted.
Cure: Try some Sleepytime Extra Tea fortified with Valerian root to help you sleep.
The only real cure for a hangover is time. Physical activity can help, too. Take a walk or jog and sweat a bit to help get the alcohol out of your blood. Fear not, the after effects of your partying should only linger for about 24 hours. Tomorrow is another day.
Source
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
OBJECTIVE. The purpose of this work was to investigate the clinical manifestations and diagnostic range of malignant entities presenting as a nasal mass in the pediatric population.
PATIENTS AND METHODS. A retrospective cohort analysis was conducted at a specialty hospital and a tertiary care university hospital. Patients aged between birth and 18 years and diagnosed with a malignancy that arose within the nasal cavity between the years 1991 and 2006 were included. This institution-specific patient group was compared with a similar cohort of patients extracted from the national Surveillance Epidemiology and End Results database. The main outcome measures were the incidence, presentation, and diagnoses of nasal cancer presenting in this population.
RESULTS. Sixteen patients with nasal malignancies presented institutionally in the defined pediatric age group. Patient age at the time of diagnosis ranged from 7 months to 17 years, with a slight male predominance. The main presenting symptoms were unilateral nasal congestion and ophthalmologic complaints. The median time from presentation to diagnosis was 7 weeks; patients who presented with nonspecific complaints, such as nasal obstruction, headache, and fatigue, were given a diagnosis, on average, later than those who presented with focal manifestations. Nationwide, 47 patients were identified from the Surveillance Epidemiology and End Results database. In both subject groups, the most common diagnoses were rhabdomyosarcoma (37.5% institutionally and 23% in the Surveillance Epidemiology and End Results group) and esthesioneuroblastoma (25% institutionally and 28% Surveillance Epidemiology and End Results). In the Surveillance Epidemiology and End Results cohort, the overall mean survival rate was 188 months.
CONCLUSIONS. Nasal cancer in the pediatric population often presents with nonspecific signs and symptoms, and a high index of suspicion is necessary for a timely diagnosis. Soft tissue sarcomas are expectedly common. The relative high frequency of esthesioneuroblastoma is particularly noteworthy. (Source: PEDIATRICS)
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Background: Little information is available about the diagnosis and management of acute methotrexate (MTX)-induced encephalopathy.
Methods: We reviewed clinical and magnetic resonance imaging (MRI) [including diffusion-weighted imaging (DWI)] characteristics of this complication in pediatric cancer patients treated from 2000 to 2006.
Results: Six of 754 (0.8%) patients with leukemia or lymphoma and 2 of 44 (4.5%) with bone sarcoma experienced acute encephalopathy within 2 weeks (median, 7.5 days) after receiving high-dose i.v. and/or intrathecal MTX. The signs and symptoms varied at presentation and during episodes: hemiparesis (eight patients, alternating from side to side in four), dysphasia (six), confusion/emotionality (six), headache (three), choreoathetosis (two), and seizure (two). All patients recovered after 1–7 days (median, 5.5 days). DWI revealed restricted diffusion in anatomic brain regions associated with the symptoms; changes on T2-weighted and fluid-attenuated inversion recovery (FLAIR) imaging were consistently less marked. After recovery, DWI findings were normal but T2 and/or FLAIR imaging usually showed residual abnormalities.
Conclusions: Acute MTX toxicity often manifests as fluctuating neurologic symptoms with alternating hemispheric involvement. Restricted diffusion on DWI is a reliable early sign of acute MTX encephalopathy and resolves as clinical status improves, despite the persistence of subtle abnormalities on MRI. (Source: Annals of Oncology)
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
International Journal of Andrology, Volume 0, Issue 0, Page ???, OnlineEarly Articles.
SummaryComparisons of incidence estimates of testicular cancer subtypes beyond seminoma and non-seminoma are virtually missing in the epidemiologic literature. We analysed incidence data from population-based German cancer registries to provide subtype-… (Source: International Journal of Andrology)
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
